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Hepatocyte growth factor (HGF), an endogenous tissue repair factor, attenuates apoptosis in many primary cell types, but
the mechanism is not completely understood. Our laboratory demonstrated that angiotensin (Ang) II activates the
intrinsic apoptotic pathway in primary endothelial cells (ECs) via reduction of the antiapoptotic protein Bcl-xL. Ang II
decreased Bcl-xL mRNA half-life by reducing its binding to nucleolin, a protein that normally binds a 3 AU-rich region
and stabilizes Bcl-xL mRNA. We hypothesized HGF may block apoptosis induced by Ang II. We used primary EC and ex
vivo cultures of rat lung tissue to investigate HGF inhibition of Ang II-induced apoptosis. Our data indicated HGF
abrogated Ang II-induced apoptosis by inhibiting cytochrome c release, caspase-3 activation, and DNA fragmentation.
RNA-immunoprecipitation experiments demonstrated that HGF stabilized Bcl-xL mRNA by increasing nucleolin binding
to the 3-untranslated region that was associated with cytoplasmic localization of nucleolin. Cytoplasmic localization of
nucleolin and Bcl-xL mRNA stabilization required HGF activation of extracellular signal-regulated kinase (ERK)1/2, but
not phosphatidylinositol 3-kinase. HGF also blocked Ang II-induced caspase-3 activation and lactate dehydrogenase
release in tissue explants in an ERK-dependent manner.
INTRODUCTION
Hepatocyte growth factor (HGF) was originally identiﬁed as
a potent mitogen for mature hepatocytes but has since been
demonstrated to exert potent motogenic, mitogenic, and
morphogenic activities in cells of epithelial and endothelial
origin (Rubin et al., 1993). HGF activity plays a critical role in
embryogenesis and organogenesis, but in the adult HGF
functions in a variety of organs as a tissue repair factor
(Matsumoto and Nakamura, 1993; Rubin et al., 1993). HGF
promotes normal repair and prevents aberrant wound
healing in several organ systems, including the lung,
heart, kidney, and liver (Matsumoto and Nakamura, 1993;
Kawaida et al., 1994; Kosai et al., 1999; Dohi et al., 2000; Kitta
et al., 2001). Animal studies show that administration of
HGF induces proliferation of epithelial and endothelial cells
and is believed to contribute to normal tissue regeneration.
The simultaneous or delayed administration of HGF protein
to mice with bleomycin-induced lung injury was demon-
strated to block ﬁbrotic remodeling, including the preven-
tion of epithelial cell apoptosis, the inhibition of ﬁbroblast
foci, and the inhibition of collagen accumulation (Yaek-
ashiwa et al., 1997; Dohi et al., 2000). Ectopic expression of
HGF, using either adenoviral expression or in vivo plasmid
transient transfection, also was shown to inhibit bleomycin-
induced lung remodeling (Ebina et al., 2002; Watanabe et al.,
2005).
Met, the HGF receptor, is a tyrosine kinase receptor with
a single transmembrane domain. HGF binding to Met in-
duces phosphorylation in the tyrosine kinase domain as well
as in a carboxy-terminal multifunctional docking domain,
the site of activation of downstream signaling pathways
(Ponzetto et al., 1994). Among the pathways activated by
HGF are the extracellular signal-regulated kinase (ERK)1/2
mitogen-activated protein kinase (MAPK) and the phospha-
tidylinositol 3-kinase (PI3K)/Akt pathways, both associated
with cellular survival and growth (Brunet et al., 1999; Day et
al., 1999; Lee et al., 2008). The activation of cell survival and
proliferation is thought to be critical for the antiﬁbrotic func-
tions of HGF (Kitta et al., 2001; Matsumoto and Nakamura,
2001).
Angiotensin (Ang) II was ﬁrst studied for its role in blood
pressure homeostasis but has more recently been shown to
play a key role in ﬁbrosis of lung, liver, kidney, and heart
(Konigshoff et al., 2007; Wynn, 2008). Ang II is believed to
play a dual role in the progression of dysfunctional wound
repair by promoting the apoptosis of tissue epithelial and
endothelial cells as well as inducing the growth and trans-
differentiation of myoﬁbroblasts (Filippatos et al., 2001; Mar-
shall et al., 2004). Local synthesis of Ang II has been observed
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4240in ﬁbrotic plaques, and human myoﬁbroblasts from patients
with idiopathic pulmonary ﬁbrosis were found to generate
Ang II (Wang et al., 1999a). Furthermore, the inhibition of
Ang II signaling was associated with the reduction of epi-
thelial and endothelial cell apoptosis in an animal model of
pulmonary ﬁbrosis (Wang et al., 2000). Studies showed that
Ang II induced apoptosis via the intrinsic apoptotic pathway
in lung epithelial cells (Wang et al., 1999b).
Our laboratory recently demonstrated that Ang II acti-
vates the intrinsic apoptotic pathway in primary endothelial
cells (ECs), including the release of cytochrome c, the acti-
vation of caspase-3, and caused DNA laddering (Lee et al.,
2010). Ang II treatment of ECs resulted in the loss of Bcl-xL
protein through the destabilization of its mRNA. We found
that Ang II induced Src homology 2 domain-containing
protein tyrosine phosphatase- (SHP-2-) dependent nuclear
translocation of nucleolin, thus preventing its binding to the
Bcl-xL mRNA 3-untranslated region (UTR), leading to
Bcl-xL mRNA instability and degradation and allowing the
activation of the intrinsic apoptotic pathway.
Here, we examined the effects of HGF on Ang II-induced
apoptosis in primary cultures of ECs. HGF inhibited the
release of cytochrome c and activation of caspase-3 in re-
sponse to Ang II. HGF protected the Bcl-xL mRNA from Ang
II-induced degradation in an ERK1/2-mediated nucleolin-
dependent pathway. Together, these data suggest that HGF
protects endothelial cells against Ang II-induced apoptosis
via activated ERK1/2-mediated cytoplasmic localization of
nucleolin that stabilizes Bcl-xL mRNA, thus inhibiting the
intrinsic apoptotic pathway.
MATERIALS AND METHODS
Reagents
Angiotensin II was purchased from Bachem (Torrance, CA). Antibodies
against cytochrome c and -actin were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA); anti-cleaved caspase-3 was purchased from Cell
Signaling Technology (Danvers, MA). The Renilla-Bcl-xL construct was the gift
of Dr. Tim Bowden (University of Arizona, Tucson, AZ; Zhang et al., 2008a).
Puriﬁed human HGF was the gift of Dr. G. F. Vande Woude (Van Andel
Research Institute, Grand Rapids, MI). Dominant-negative Ras in an adeno-
viral expression vector was provided by Dr. M. L. Cutler (Uniformed Services
University of the Health Sciences, Bethesda, MD). Constitutively active and
dominant-negative (DN) mitogen-activated protein kinase kinase (MEK) 1 in
an adenoviral expression vector was the gift of Dr. Y. J. Suzuki (Georgetown
University, Washington, DC).
Cell Culture
Bovine pulmonary artery ECs were purchased from American Type Culture
Collection (Manassas, VA). Passages 2–8 cells were used for all experiments
and were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA) contain-
ing 10% fetal bovine serum (FBS) (Gemini Bioproducts, Woodland, CA), 1%
penicillin/streptomycin, and 0.5% Fungizone (Invitrogen). Cells were grown
in 5% CO2 at 37°C in a humidiﬁed atmosphere in a culture incubator.
Cell Lysate
Cells were washed with ice-cold phosphate-buffered saline (PBS) and lysed in
50 mM HEPES, pH 7.4, 1% (vol/vol) Triton X-100, 4 mM EDTA, 1 mM sodium
ﬂuoride, 0.1 mM sodium orthovanadate, 1 mM tetrasodium pyrophosphate, 2
mM phenylmethylsulfonyl ﬂuoride, 10 g/ml leupeptin, and 10 g/ml apro-
tinin. Lysates were incubated 15 min on ice and then vortexed; insoluble
materials were removed by centrifugation (14,000  g for 10 min at 4°C). For
immunoprecipitation of Bax, cells were washed with cold PBS and lysed in
3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS) buffer
[50 mM Tris-HCl, 1 mM EGTA, 1% (wt/vol) CHAPS, 10% glycerol, 50 mM
sodium ﬂuoride, 1 mM sodium orthovanadate, 2 mM phenylmethylsulfonyl
ﬂuoride, 10 g/ml leupeptin, and 10 g/ml aprotinin]. Equal concentrations
of protein from cell lysates were incubated with primary antibody (1:1000
dilution). GammaBind Plus beads (1:100 dilution; GE Healthcare, Little Chal-
font, Buckinghamshire, United Kingdom) were added and samples were
rotated at 4°C overnight. The beads were centrifuged at 10,000  g for 10 min
at 4°C and washed twice with lysis buffer containing protease and phospha-
tase inhibitors. To elute, beads were resuspended in 25 l of Laemmli buffer
incubated for 5 min at 95°C.
Western Blots
Whole cell lysates (10 g of total protein) were subjected to SDS-polyacryl-
amide gel electrophoresis and electroblotted onto nitrocellulose membrane.
Membranes were blocked with 5% bovine serum albumin (BSA) in Tween
20/Tris-buffered saline (TTBS) for1ha tambient temperature. Membranes
were then incubated overnight at 4°C with primary antibody (1:1000 dilution)
in TTBS containing 0.5% (wt/vol) BSA. Membranes were washed three times
with TTBS for 10 min, followed by incubation with horseradish peroxidase-
labeled secondary antibody (1:1000 in TTBS) for1ha tambient temperature.
For protein detection, membranes were washed for 3 h with TBS, incubated in
ECL solution (Pierce Chemical, Rockford, IL), and analyzed on a LAS-1000Pro
image reader (FujiFilm USA, Valhalla, NY).
Mitochondria and Mitochondria-free Cytosolic Protein
Extraction
Mitochondria extraction was performed using the mitochondria isolation kit
for cultured cells according to the manufacturer’s protocol (Pierce Chemical).
Neutral Comet Assay
The neutral comet assay was used to measure double-stranded DNA breaks
as an indication of apoptosis (Lee et al., 2010). After treatment, cells were
embedded in 1% (wt/vol) low-melting agarose and placed on comet slides
(Trevigen, Gaithersburg, MD). Slides were placed in lysis solution (2.5 M
NaCl, 1% Na-lauryl sarcosinate, 100 mM EDTA, 10 mM Tris base, and 0.01%
Triton X-100) for 30 min, followed by a wash in 1 Tris borate-EDTA (TBE)
buffer (0.089 M Tris, 0.089 M boric acid, and 0.002 M EDTA, pH 8.0). Nuclei
were electrophoresed for 10 min at 18 V in 1 TBE. Cells were then ﬁxed with
75% ethanol for 10 min and air-dried overnight, stained with 1 SYBR Green
(Invitrogen) or propidium iodide (Sigma-Aldrich, St. Louis, MO), and visu-
alized with an FV500 confocal laser scanning microscope (Olympus Imaging
America, Center Valley, PA) by using 20 magniﬁcation at 478 nm excitation,
507 nm emission wavelengths for SYBR Green and at 535 nm excitation, 617
nm emission wavelengths for propidium iodide. All cells were counted in
randomly selected ﬁelds for each treatment group and assigned into type A,
B, or C comet categories, based on their tail moments. Type C comets were
deﬁned as apoptotic cells (Krown et al., 1996).
DNA Laddering Assay
Cells were harvested in the medium and pelleted at 1000  g. Pellets were
resuspended and incubated on ice in lysis buffer (1 Tris-EDTA and 0.2%
Triton, pH 8.0) for 15 min. Resuspended pellet was centrifuged (14,000  g for
10 min at 4°C), and supernatant containing the fragmented DNA was col-
lected. RNase A (ﬁnal concentration, 60 mg/ml) was added and incubated for
30 min at 37°C. SDS was added to a ﬁnal concentration of 0.5% along with 150
g/ml proteinase K and incubated2ha t50°C. Then, 0.1 volume of 5 M NaCl
and 1 volume of ice cold isopropanol were added, and samples were incu-
bated on ice for 10 min. The samples were centrifuged at 13,000  g for 15 min
at 4°C. The DNA pellet was brieﬂy dried and dissolved in 20 l of TE buffer,
followed by electrophoresis (2 h at 20 V) in 1.5% agarose.
RNA Isolation and Reverse Transcription (RT)
Total RNA was obtained from bovine ECs by using the RNeasy kit (QIAGEN,
Valencia, CA). Genomic DNA was removed using the RNase-Free DNAse
set (QIAGEN). RNA concentrations were determined spectroscopically at
260 nm (ND-1000 spectrophotometer; NanoDrop, Wilmington, DE). RNA
(1.0 g) was subjected to RT with GeneAmp RNA polymerase chain
reaction (PCR) kit according to the manufacturer’s protocol (Applied
Biosystems, Foster City, CA).
Semiquantitative RT-PCR
We used 1 l of cDNA from the RT reaction for the PCR reaction containing
0.4 M each forward and reverse primer, 200 M each dNTP,1Uo fi Taq
DNA polymerase, and 1 PCR buffer (Bio-Rad Laboratories, Hercules, CA).
The PCR primers for Bcl-xL mRNA were as follows: 5-GGT ATT GGT GAG
TCG GAT CG and 5-GCT GCA TTG TTC CCG TAG AG. PCR reactions were
optimized for annealing temperatures using a temperature gradient in an
iCycler (Bio-Rad Laboratories). Reactions were carried out for 25 cycles by
using the following conditions: 95°C 1 min, 60°C 45 s, and 72°C 1.5 min. The
last cycle extension was for 10 min at 65°C. PCR primers for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) were as follows: 5-GAA GCT CGT
CAT CAA TGG AAA and 5-CCA CTT GAT GTT GGC AGG AT. PCR
reactions were analyzed on a 1.5% agarose gel in Tris EDTA buffer, and bands
were visualized using ethidium bromide.
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Bovine ECs were treated as indicated above and then incubated with 5 g/ml
actinomycin D for time courses between 30 min and 8 h. Total RNA was
isolated and the level of Bcl-xL mRNA was determined by quantitative PCR
or by semiquantitative RT-PCR (primers listed above). Levels of GAPDH
mRNA were determined by gel electrophoresis and used for normalization of
the semiquantitative RT-PCR (primers are listed above). ImageJ software
(http://www.uhnresearch.ca/facilities/wcif/index.htm) was used for quan-
tiﬁcation.
Plasmid Transfection
One day before transfection, cells were plated at 1.4  105 cells/well in a
12-well plate. DNA (1 g/well) was transfected using the FuGENE 6 trans-
fection reagent (Roche Applied Science, San Francisco, CA), according to the
manufacturer’s instructions, in serum-free, antibiotic-free medium. For lucif-
erase assays, transfection mixtures contained a ratio of Renilla-Bcl-xL reporter
construct to luciferase control vector (RSV-Luc) of 6:1 to normalize transfec-
tion efﬁciency.
Dual-Luciferase Assay
Transfected cells were washed twice with cold PBS, lysed with passive lysis
buffer, and assayed for ﬁreﬂy and Renilla luciferase activities using the dual-
luciferase assay (Promega, Madison, WI) according to the manufacturer’s
instructions in a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA).
RNA-Immunoprecipitation (IP)
Cells were harvested by centrifugation at 1000  g for 3 min and resuspended
in 10 ml of PBS. RNA and protein complexes were cross-linked by adding of
1.0% (vol/vol), ﬁnal concentration, of formaldehyde and incubation at room
temperature for 10 min with gentle mixing. Cross-linking was quenched by
addition of glycine (pH 7.0; 0.125 mol/l, ﬁnal concentration) at room temper-
ature for 5 min. Cells were washed twice with 10 ml of PBS containing
protease and RNAse inhibitors. The pellet was resuspended in 0.2 ml of
NP-40 buffer [5 mM piperazine-N,N-bis(2-ethanesulfonic acid), pH 8.0, 85
mM KCl, 0.5% NP-40, protease inhibitors, and RNase inhibitor] and incubated
on ice for 10 min. Nuclei were pelleted by centrifugation at 1400  g for 5 min
at 4°C. Supernatant was sonicated three times for 20 s each at output level 6
of a sonic model 100 dismembrator (Thermo Fisher Scientiﬁc, Waltham, MA).
The samples were cleared by centrifugation at 14,000 rpm for 10 min at 4°C
and diluted 10-fold into IP buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris, pH 8.1, 167 mM NaCl, protease inhibitors, and RNase
inhibitor) to a ﬁnal volume of 1 ml per immunoprecipitation reaction. A 1%
aliquot was preserved as an input sample. Nucleolin antibody (1:1000 dilu-
tion) was added to each tube, and immune complexes were allowed to form
by gentle mixing on a rotating platform at 4°C overnight. To collect immune
complexes, 50 l of Sepharose beads was added and mixed gently for 2 h
followed by centrifugation at 60  g for 2 min at 4°C. The immune complexes
were washed for 5 min each with low salt (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris-HCl, pH 8.1, and 150 mM NaCl), high salt (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, and 500 mM NaCl), LiCl
(0.25M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, and 10 mM Tris-HCl.
pH 8.1), and twice with TE buffer. Each wash was followed by 60  g
centrifugation for 1 min. Immune complexes were eluted in 500 l of elution
buffer (1% SDS, 0.1 M NaHCO3, and RNase inhibitor). NaCl was added to a
ﬁnal concentration of 200 mM, and then samples were placed at 65°C for 2 h
to reverse cross-linking. Next, 20 l of 1 M Tris-Cl, pH 6.5, 10 l of 0.5 M
EDTA, and 20 g of proteinase K were added to each sample and incubated
at 42°C for 45 min. RNA was extracted using phenol:chloroform with glyco-
gen as a DNA-carrier. DNA was removed with DNase (QIAGEN). RT-PCR
was performed using 1 l of the cDNA reaction for 25 cycles: denaturing was
performed at 95°C for 1 min, annealing for 45 s at 60°C, and polymerase
reaction for 1.5 min at 72°C. Primers were as follows: Bcl-xL ARE-2, 5-ACC
TTC CTC AAT TGT CGT GG-3 and 5-GGG GAA AAG GGT CAG AAA
C-3; and Bcl-2 ARE, 5-TGC TTT TGA GGA GGG CTG CAC and 5-ACT
GCC TGC CAC AGA CCA GC.
Ex Vivo Lung Explants
All treatment of animals was according to National Institutes of Health,
Department of Defense, and institutional guidelines. Sprague Dawley rats
(Taconic Farms, Germantown, NY) were housed one female with litter per
cage in a facility accredited by the Association for Assessment and Accredi-
tation of Laboratory Animal Care International. Animal rooms were main-
tained at 21  2°C, 50  10% humidity, and 12-h light/dark cycle. Commer-
cial rodent ration (Harlan Teklad Rodent Diet 8604; Harlan, Indianapolis, IN)
and water were freely available. Rat pups were obtained on postnatal day 10
or 11. Animals were anesthetized with pentobarbital and decapitated, or
killed with Fatal-Plus. The surface of the anterior chest wall and upper
abdomen were sterilized with 70% ethanol. After the trachea was exposed, a
small nick was made to insert a 22-gauge needle with a short piece of
polyethylene tube attached. Through a midline abdominal incision the chest
cavity was exposed and the animal was exsanguinated by severing the
abdominal aorta. The right ventricle was punctured and the lungs were
perfused with sterile PBS to remove the blood. The trachea, lungs, and the
heart were then aseptically dissected from the animal.
To obtain lung slices for the ex vivo culture, the lungs were inﬂated with 1%
low melting point agarose dissolved in RPMI 1640 medium. The agarose was
instilled via the trachea by using a syringe to fully inﬂate the lungs. The
lung-heart blocks were placed in sterile cell culture plates at 4°C for at least 30
min to solidify the agarose. The heart was then excised from the lung, and
each lobe of the lung was embedded on a cutting board with 1% agarose to
prevent movement. The agarose-ﬁlled and embedded lungs were then cut
into 500-m-thick slices with a MclLwain tissue chopper (Geneq, Anjou, QC,
Canada). Slices were incubated in RPMI 1640 medium containing 10% FBS,
1% penicillin/streptomycin, and 0.5% Fungizone for an hour in 37°C in a
humidiﬁed chamber with 5% CO2. Lung slices were transferred to a 24-well
cell culture plate and treated for 16–24 h in 37°C humidiﬁed chamber with 5%
CO2.
Statistical Analysis
Means  SD were calculated, and statistically signiﬁcant differences between
two groups were determined using the Student’s t test. For three or more
groups, statistical analysis was performed using one-way analysis of variance,
followed by the Bonferroni’s post analysis, as appropriate; p  0.05 was
considered statistically signiﬁcant. For mRNA half-life, linear regression was
calculated and conﬁdence intervals were determined. Statistical software for
all analysis was SigmaStat 3.1 (Systat Software, Point Richmond, CA).
RESULTS
HGF Inhibits Ang II-induced Intrinsic Apoptosis
HGF attenuates cellular apoptosis associated with ﬁbrotic
remodeling in the lung (Yaekashiwa et al., 1997; Dohi et al.,
2000), but the mechanism of this activity is not completely
understood. Previously, our laboratory reported that the
proﬁbrotic agent Ang II induces the intrinsic apoptotic path-
way in primary ECs, with DNA fragmentation occurring
within 24 h (Lee et al., 2010). We investigated the effect of
HGF on Ang II-induced apoptosis in ECs by using the
neutral comet assay, which detects chromosomal fragmen-
tation as a function of apoptosis. Treatment with Ang II
alone resulted in 65% apoptosis within 24 h. Pretreatment
with HGF inhibited the Ang II-induced apoptosis, resulting
in only 20% apoptosis (p  0.05) (Figure 1A). To conﬁrm that
the cells are indeed undergoing apoptosis, we performed
DNA laddering experiments. Data show that 25 ng/ml HGF
pretreatment inhibited Ang II-induced DNA laddering (Fig-
ure 1B). HGF also prevented Ang II-induced caspase-3 acti-
vation and mitochondrial release of cytochrome c, as deter-
mined by western blot (Figure 1C).
HGF Inhibits Ang II Reduction of Bcl-xL mRNA Half-Life
The down-regulation of anti-apoptotic members of the Bcl-2
family, relative to proapoptotic family members is sufﬁcient
to induce apoptosis. Our laboratory demonstrated that Ang
II treatment of EC decreased levels of the anti-apoptotic
protein Bcl-xL and thereby reduced interaction of Bcl-xL with
the proapoptotic Bax protein (Lee et al., 2010). Pretreatment
of EC with HGF before exposure to Ang II restored Bcl-xL
protein expression to basal levels (Figure 2A) and preserved
its interaction with Bax (Figure 2B).
We demonstrated previously that Ang II decreases the
half-life of Bcl-xL mRNA (Lee et al., 2010). We therefore
hypothesized that HGF would prevent Ang II-induced deg-
radation of Bcl-xL mRNA. The level of Bcl-xL mRNA in the
cells pretreated with HGF was stabilized in the presence of
Ang II treatment (Figure 2C). These data suggest that one
mechanism by which HGF prevents Ang II-induced de-
crease of Bcl-xL protein levels is through stabilization of the
Bcl-xL mRNA.
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Binding of the Met receptor by HGF leads to the activation
of two major antiapoptotic pathways, the ERK1/2 MAPK
pathway and the PI3K pathway. We demonstrated that
these pathways are both activated by HGF in ECs (Lee et al.,
2008). We investigated whether HGF uses the ERK1/2 or the
PI3K pathway to inhibit Ang II-induced apoptosis. EC were
Figure 1. HGF inhibits Ang II-induced intrin-
sic apoptosis in ECs. ECs were grown to 80%
conﬂuence and starved in 0.01% FBS media
overnight. Cells were treated with HGF (25
ng/ml) for 20 min before 10 M Ang II for 24 h.
(A) Neutral comet assay on HGF and Ang II-
treated EC was done. The percentage of apo-
ptotic cells are indicated. Data show means 
SD, n  4. Asterisk (*) indicates statistical sig-
niﬁcance from control, p  0.05. Dagger (†)
indicates statistical signiﬁcance from Ang II
alone, p  0.05. (B) Equal amounts of DNA
were electrophoresed in agarose gels to visual-
ize DNA laddering; representative data are
shown. (C) Cells were lysed and mitochondria
were removed from the cytosolic components.
Cytosolic lysates were western blotted for cy-
tochrome c and cleaved caspase-3. Right panels
indicate densitometries, normalized to -actin.
Data show mean band density normalized to
actin  SD, n  4. Asterisk (*) indicates statis-
tical signiﬁcance from control, p  0.05. All
experiments were repeated at least four times.
Figure 2. HGF inhibits Ang II-induced re-
duction of Bcl-xL protein and mRNA. ECs were
grown to 80% conﬂuence and were placed in
low serum (0.01% FBS) overnight. Cells were
pretreated with HGF (25 ng/ml) for 20 min
before treatment with 10 M Ang II for 16 h.
(A) Cell lysates were immunoblotted for Bcl-xL
protein expression; blots were stripped and re-
probed for -actin. Bottom panel shows densi-
tometry of Bcl-xL normalized to -actin from
three independent experiments. (B) Equal
amounts of protein from cell lysates were im-
munoprecipitated for Bax and western blotted
for Bcl-xL. Blots were stripped and blotted for
Bax. Bottom panel shows densitometry of
Bcl-xL normalized to Bax from three indepen-
dent experiments. (C) Cells were pretreated
with HGF (25 ng/ml) for 20 min before treat-
ment with 10 M Ang II for 8 h. After the
treatment, 5 g/ml actinomycin D was added.
At various time points, total RNA was ex-
tracted, and the levels of Bcl-xL mRNA were
determined by RT-PCR. GAPDH was deter-
mined by RT-PCR as a control. For all graphs,
data show means,  SD, n  3. Asterisk (*)
indicates statistical signiﬁcance from control,
p  0.05. At least three independent experi-
ments were performed.
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hibitor U0126 that blocks activation of ERK1/2 or LY294002
that inhibits PI3K activity. Ang II treatment alone induced
75% apoptosis, and HGF pretreatment inhibited the cell
death to 20%, slightly above control levels (Figure 3A).
U0126 treatment with HGF before the addition of Ang II
eliminated HGF protection, and apoptosis was not statisti-
cally different from the addition of Ang II alone. LY294002
treatment had no signiﬁcant effect on HGF inhibition of Ang
II-induced apoptosis. When treated with both U0126 and
LY294002 treatment before HGF and Ang II, the level of
apoptosis was not signiﬁcantly different from the level of
apoptosis when U0126 was used alone. Addition of HGF,
U0126, or LY294002 in the absence of Ang II did not
induce signiﬁcant apoptosis. Similar results were seen
when using cleaved caspase-3 as a marker of apoptosis
(Figure 3B). Ang II induced an 3.5-fold increase in the
band density of cleaved caspase-3 compared with control.
HGF treatment reduced caspase-3 activation to basal lev-
els. The inhibitory activity of HGF was signiﬁcantly
blocked by pretreatment with either U0126 or LY294002,
although U0126 treatment demonstrated a greater inhibi-
tion of HGF activity. Addition of U0126 with LY294002
completely blocked HGF inhibition of Ang II-induced
caspase-3 activation. The addition of HGF, U0126, or
LY294002 in the absence of Ang II did not increase caspase
activation above basal levels.
RAS and MEK1/2 are upstream signaling molecules of
ERK1/2 pathway in Met signaling (Zhang and Vande
Woude, 2003). Therefore, we used DN RAS to determine
whether cell survival by HGF is also RAS dependent. DN
RAS suppressed HGF-induced cell survival (Figure 3C).
We next investigated the effect of overexpression of con-
stitutively active (CA) MEK1 in ECs on Ang II-induced
apoptosis. CA MEK1 overexpression provided complete
inhibition of Ang II-induced apoptosis and did not affect
the antiapoptotic activity of HGF (Figure 3D). Together
these results suggest that HGF activation of Ras is required for
its antiapoptotic activity, and activation of MEK1 alone is suf-
ﬁcient to inhibit Ang II-induced apoptosis.
HGF Protects the Interaction between Cytoplasmic
Nucleolin and the 3-UTR of the Bcl-xL mRNA
Nucleolin protein binds to 3-UTR of Bcl-xL mRNA to sta-
bilize the mRNA and prevent its degradation (Zhang et al.,
2008a). Our laboratory showed that Ang II causes displace-
ment of nucleolin from the Bcl-xL mRNA in ECs, resulting in
a decreased half-life of the mRNA (Lee et al., 2010). RNA-IP
was performed to test whether HGF prevents Ang II-in-
duced displacement of nucleolin from Bcl-xL mRNA. Ang II
AC
BD
Figure 3. HGF-activated ERK1/2, but not PI3K, is necessary to inhibit apoptosis. (A and B) ECs were grown to 80% conﬂuence and were
placed in low serum (0.01% FBS) overnight. Cells were then pretreated with U0126 (10 M), LY294002 (10 M), HGF (25 ng/ml), or a
combination for 20 min before treatment with 10 M Ang II for 24 h. (A) Neutral comet assay. (B) Immunoblotting, using equal amounts of
protein from whole cell lysates, was performed to determine the levels of cleaved caspase-3. Blots were stripped and blotted for -actin to
control for protein loading. (C and D) ECs were grown to 80% conﬂuence and infected with adenovirus DN RAS or CA MEK for 48 h. Cells
were then pretreated with HGF (25 ng/ml) for 20 min before treatment with 10 M Ang II for 24 h. Neutral comet assay was performed. Data
show means  SD, n  4. Asterisk (*) indicates statistical signiﬁcance from control, p  0.05. Dagger (†) indicates statistical signiﬁcance from
Ang II alone, p  0.05. Experiments were repeated at least four times.
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60% (Figure 4A). HGF pretreatment maintained the Bcl-
xL–nucleolin complex at basal levels. To conﬁrm these ﬁnd-
ings, we tested the effects of HGF on a Renilla expression
construct containing the Bcl-xL 3-UTR that is responsive to
nucleolin stabilization (Zhang et al., 2008a). Ang II decreased
the levels of Renilla-Bcl-xL by 75% (Figure 4B). In contrast,
HGF pretreatment inhibited the Ang II-induced decrease,
restoring the levels of Renilla to basal levels. These data
indicate that HGF prevents Ang II-induced disassociation
between nucleolin and Bcl-xL mRNA.
HGF Blocks Ang II-induced Translocation of Nucleolin to
the Nucleus
In apoptotic cells, nucleolin has been observed to undergo
nuclear translocation as well as proteolytic processing
(Srivastava and Pollard, 1999; Kito et al., 2003). We hy-
pothesized that Ang II-induced nuclear translocation,
degradation, or both of nucleolin might contribute to the
decreased availability of nucleolin for binding to the
Bcl-xL mRNA; we further hypothesized that HGF might
prevent the degradation or nuclear localization of nucleo-
lin. Nuclear and cytoplasmic fractions were examined for
nucleolin protein by using western blot analysis after Ang
II treatment, HGF treatment, or both of ECs. Ang II de-
creased the cytoplasmic levels of nucleolin protein by
70% and signiﬁcantly increased nucleolin levels in the
nucleus compared with control (Figure 5). Although other
researchers have reported that nucleolin may undergo
proteolysis during apoptosis, we did not detect lower-
molecular-weight bands under our experimental condi-
tions (data not shown). HGF inhibited the Ang II-induced
translocation of nucleolin from the cytoplasm to the nu-
cleus, maintaining nucleolin in the cytoplasm to near
basal levels. These data indicate that Ang II reduces the
level of nucleolin in the cytoplasm via nuclear transloca-
tion and that HGF inhibits this relocalization.
HGF Stabilization of the Binding of Nucleolin to the
Bcl-xL 3-UTR Requires ERK1/2 Pathway
Prior studies of HGF-induced cell survival suggested the
involvement of two major pathways for this activity: the
ERK1/2 and PI3K/Akt pathways (Day et al., 1999; Fan et
al., 2000). To determine which pathway HGF uses for
stabilization of the nucleolin–Bcl-xL mRNA complex, cells
were treated with either the MEK1/2 inhibitor U0126 or
PI3K inhibitor LY294002 before the addition HGF and
Ang II. Pretreatment with U0126 blocked the effect of HGF
on Ang II-induced localization of nucleolin to the nucleus
(Figure 6, A and B). However, LY294002 treatment did not
affect HGF inhibition of Ang II-induced nucleolin trans-
location. We next examined the effect of inhibiting the
ERK1/2 pathway on the Bcl-xL mRNA levels. In agree-
ment with our previous ﬁndings, quantitative RT-PCR
showed that the MEK1/2 inhibitor U0126 blocked HGF
inhibition of Ang II-induced down-regulation Bcl-xL
mRNA (Figure 6C). Again, LY294002 treatment did not
alter the level of the Bcl-xL mRNA induced by HGF treat-
ment (Figure 6C). Using the Renilla expression construct
containing the Bcl-xL 3-UTR, we observed that HGF in-
hibited Ang II-induced decrease of Renilla expression
(Figure 6D). Interestingly, levels of Renilla-Bcl-xL 3-UTR
levels were increased by HGF treatment alone to 20%
over control levels. ERK1/2 inhibition prevented HGF
inhibition of Ang II destabilization of the Renilla reporter
(Figure 6D). We found that LY294002 does not prevent
HGF inhibition of Ang II destabilization of the Renilla
reporter (data not shown).
A
B
Figure 4. HGF stabilizes Bcl-xL mRNA binding to nucleolin. ECs
were grown to 80% conﬂuence and were placed in low serum
(0.01% FBS) overnight. Cells were then pretreated with HGF (25
ng/ml) for 20 min before treatment with 10 M Ang II for 24 h. (A)
Cells were ﬁxed and RNA-IP was performed using the C23-nucleo-
lin antibody. RNA–protein complex was reverse cross-linked for
2 h, and proteinase K and DNase were added. Phenol:chloroform
RNA extraction was performed for cDNA synthesis. PCR was per-
formed for the second AU-rich region of the 3-UTR of Bcl-xL.
Bottom panel shows densitometry of Bcl-xL mRNA band. Data
show means  SD, n  3. Asterisk (*) indicates statistical signiﬁ-
cance from control, p  0.05. (B) Cells were transfected with Renilla-
Bcl-xL 3-UTR and cotransfected with a luciferase vector RSV-Luc
construct to normalize for transfection efﬁciency. Six hours after
transfection, cells were placed in serum-free medium. Cells were
pretreated  HGF (25 ng/ml) before treatment with 10 M Ang II
for 16 h. Luciferase and Renilla assays were performed on cell
lysates. Data show means  SD. Asterisk (*) indicates statistical
signiﬁcance from control, p  0.05, n  3. Experiments were re-
peated at least three times.
AB
Figure 5. HGF blocks nucleolin translocation to the nucleus. ECs
were grown to 80% conﬂuence and were placed in low serum
(0.01% FBS) overnight. Cells were then pre-treated with HGF (25
ng/ml) for 20 min before treatment with 10 M Ang II for 24 h.
After Ang II  HGF treatment, cytosolic and nuclear fractions
were used for nucleolin immunoblotting. Blots were stripped and
blotted for -actin to control for protein loading. Data show
means  SD, n  3. Asterisk (*) indicates statistical signiﬁcance
from control, p  0.05. Experiments were repeated at least three
times.
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way, EC were infected with adenovirus DN Ras or CA
MEK1. When the cells were infected with DN Ras, the
level of Bcl-xL decreased signiﬁcantly even with the HGF
treatment (Figure 6E). In addition, dominant-negative
RAS inhibited HGF-induced ERK activation, showing that
ERK activation by HGF is downstream of RAS activation
(Figure 6E). In contrast, constitutively active MEK1 ex-
Figure 6. The ERK1/2 pathway is required
for HGF localization of nucleolin to the cyto-
plasm. (A–C) ECs were grown to 80% conﬂu-
ence and were placed in low serum (0.01% FBS)
overnight. Cells were then pretreated with
HGF (25 ng/ml) for 20 min  either LY294002
(10 M) or U0126 (10 M) for 20 min, before
the addition of 10 M Ang II for 24 h. (A)
Cytosolic extracts were analyzed for the
nucleolin protein by using western blotting. (B)
Nuclear extracts were analyzed for the nucleo-
lin protein by using immunoblotting. Blots
were stripped and blotted for -actin to control
for protein loading. All data show means  SD,
n  3. Asterisk (*) indicates statistical signiﬁ-
cance from control, p  0.05. Experiments were
repeated at least three times. (C) RNA-IP was
performed for nucleolin followed by PCR am-
pliﬁcation for the second AU-rich region of the
3-UTR of Bcl-xL. (D) ECs were transfected with
Renilla-Bcl-xL 3-UTR and cotransfected with a
luciferase vector RSV-Luc construct to normal-
ize for transfection efﬁciency. Six hours after
transfection, cells were placed in serum-free
medium. Cells were pretreated  U0126 (10
M) before treatment with HGF (25 ng/ml) for
16 h. Luciferase and Renilla assays were per-
formed on cell lysates. Data show means  SD.
Asterisk (*) indicates statistical signiﬁcance
from control, p  0.05, n  4. Experiments
were repeated at least four times. (E) ECs were
grown to 80% conﬂuence and infected with
adenovirus for 48 h. Cells were then pretreated
with HGF (25 ng/ml) for 20 min before treat-
ment with 10 M Ang II for 24 h. Immunoblot-
ting, using equal amounts of protein from
whole cell lysates, was performed to determine
the levels of Bcl-xL and phospho-MAPK
(pMAPK). Blots were stripped and blotted for
total MAPK (tMAPK) and -actin to control for
protein loading. Data show means  SD, n  3.
Asterisk (*) indicates statistical signiﬁcance
from control, p  0.05. Dagger (†) indicates
statistical signiﬁcance from Ang II alone, p 
0.05. Experiments were repeated at least three
times.
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Together, these data suggest that HGF-activated ERK1/2,
but not PI3K, is required for HGF-induced cytoplasmic lo-
calization of nucleolin and stabilization of Bcl-xL mRNA.
HGF Inhibits Ang II-induced Apoptosis in Ex Vivo Rat
Lung Tissue
Ex vivo lung slice cultures have been used as an alternative
to in vivo experiments for measuring cellular signaling
mechanisms. In the ex vivo method, an isolated organ sus-
tains the architecture and functionality of the tissue, thus
represents a closer model to in vivo than the in vitro mono-
layer models from a single cell type. Studies have shown
that alveolar cells divide and correctly differentiate in ex
vivo lung slice cultures (Kinnard et al., 1994), and this tech-
nique has been used for apoptosis and cell survival studies
(Li et al., 2003; Lang et al., 2007; Hackett et al., 2008). The ex
vivo lung model has been demonstrated to act as a reliable
model for in vivo studies of the role of Ang II signaling
inducing lung cell apoptosis downstream of proﬁbrotic
stimuli (Li et al., 2003; Mancini and Khalil, 2005). We there-
fore used lung explants with Ang II treatment with or with-
out HGF to verify our EC monoculture ﬁndings. A lactate
dehydrogenase (LDH)-cytotoxicity assay was performed to
evaluate cell death. Ang II treatment induced an 2.4-fold
increase in LDH levels compared with the untreated control
(Figure 7A). Cotreatment of Ang II with HGF reduced LDH
to basal levels.
Ang II activated proapoptotic proteins in the lung slice
explants, consistent with our ﬁndings in EC cultures (Figure
7B). The data demonstrate that HGF inhibited cleaved
caspase-3 induced by Ang II treatment. Ang II treatment
also lowered the level of Bcl-xL protein level, but with HGF,
the level of Bcl-xL protein was similar to the control (Figure
7B). Interestingly, treatment of the lung explants with HGF
alone reduced levels of caspase-3 and increased levels of
Bcl-xL protein compared with basal levels. This suggests that
HGF prevents cell death that might occur from the process-
ing of the tissue for slice cultures.
HGF Activated ERK1/2 Inhibits Ang II-induced Apoptosis
in Ex Vivo Rat Lung Slices
To conﬁrm that HGF activation of ERK1/2 is necessary to
inhibit Ang II-induced apoptosis in explant tissue, we ﬁrst
used chemical MEK1/2 inhibitor U0126. Ang II treatment of
ex vivo rat lung explants increased levels of cleaved
caspase-3, but pretreatment with HGF prevented cleavage of
caspase-3 (Figure 8A, top). When the lung slices were pre-
treated with U0126 before HGF and Ang II treatments, the
level of active caspase-3 increased. To verify that U0126 can
enter and inhibit MEK in the tissue, a control experiment
was performed, showing that phosphorylated ERK1/2 is
present in the tissue and can be inhibited by U0126 (Figure
8A, bottom). Next, we used overexpression of DN MEK1 to
verify our ﬁndings using pharmacological inhibition of MEK
to block ERK1/2 activation. Lung explant tissues were in-
fected with either adenovirus-encoded green ﬂuorescent
protein (GFP), as a control, or adenovirus-encoded DN
MEK1. Adenovirus-GFP was used to conﬁrm viral incorpo-
ration and gene expression in the lung ex vivo explants (data
not shown). After infection, lung explants were treated with
HGF and Ang II. Overexpression of GFP did not affect HGF
activation of ERK1/2, but overexpression of DN MEK1
blocked this activation (Figure 8B, left). Adenovirus-GFP
tissues treated with Ang II contained increased active
caspase-3, but HGF treatment signiﬁcantly reduced cleaved
caspase-3 levels (Figure 8B, right). Adenovirus-DN MEK1-
infected tissue showed increased levels of caspase-3 activa-
tion in the presence of Ang II as well as HGF (Figure 8B,
right). Together, the data suggest that HGF uses the ERK1/2
pathway to inhibit apoptosis in lung explant tissue.
DISCUSSION
HGF has been demonstrated to function as an antiﬁbrotic
factor, but the mechanism of this activity is not completely
understood. Here, we demonstrate that HGF inhibits the
apoptotic activity of Ang II, a key factor in the progression of
ﬁbrotic organ diseases (Filippatos et al., 2001; Marshall et al.,
2004; Konigshoff et al., 2007; Wynn, 2008). We found previ-
ously that Ang II induces the intrinsic mechanism of apo-
ptosis in EC through the reduction of Bcl-xL protein and
mRNA levels (Lee et al., 2010). In our current work, we
demonstrate using both in vitro and ex vivo models that
HGF inhibits Ang II-induced apoptosis, blocking cyto-
chrome c release from the mitochondria, caspase-3 activa-
tion, and DNA fragmentation. This blockade involves the
stabilization of anti-apoptotic Bcl-xL mRNA via the binding
of nucleolin. Our data indicate that HGF inhibition of Ang
II-induced apoptosis, including stabilization of Bcl-xL
mRNA, is dependent upon the activation of ERK1/2.
In cancer cells, the mechanism of HGF-induced cell
growth and inhibition of apoptosis has been shown to in-
volve two major pathways, ERK1/2 and PI3K (Day et al.,
1999; Fan et al., 2000; Xiao et al., 2001). Others have shown
that HGF can inhibit the intrinsic apoptotic pathway by dual
mechanisms, involving phosphorylation and deactivation of
proapoptotic Bcl-2 family members as well as the up-regu-
lation of antiapoptotic Bcl-2 family members (del Peso et al.,
1997; Zhang et al., 2008b). PI3K has shown to increase Bcl-xL
gene expression to prevent apoptosis in some cell types
(Umeda et al., 2003). In addition, previous studies have
shown that Akt, a kinase activated downstream of PI3K,
exerts antiapoptotic effects through the phosphorylation of
Figure 7. HGF inhibits Ang II-induced apo-
ptosis in rat lung ex vivo cultures. (A and B)
Rat lung slices were cultured overnight in a
media containing 10 M Ang II  HGF (25
ng/ml) for 24 h. (A) Cell media were collected
to quantify the LDH release. (B) Lung slice
tissue was homogenized and the protein ly-
sates were used for western blots to determine
the levels of Bcl-xL and activated caspase-3.
Data show means  SD. Asterisk (*) indicates
statistical signiﬁcance from control, p  0.05,
n  4. Experiments were repeated at least four
times.
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reports indicate that ERK1/2 also increases cell survival by
several mechanisms, including via the regulation of the
phosphorylation state of antiapoptotic proteins (Horiuchi et
al., 1997; Ito et al., 1997). Both PI3K and ERK1/2 pathways
are activated by HGF to decrease caspase-3 activation after
serum starvation or UV irradiation, although it is not known
whether these effects are direct or indirect (Xiao et al., 2001).
Our current ﬁndings indicate that ERK1/2 inhibition, but
not PI3K inhibition, blocks HGF survival activity in the
presence of Ang II. Our data indicate that activation of the
ERK1/2 pathway is both necessary and sufﬁcient to inhibit
Ang II-induced apoptosis. Results from cell culture experi-
ments using the overexpression of CA MEK1 demonstrate
that CA MEK1 alone prevents degradation of antiapoptotic
Bcl-xL protein and inhibits Ang II-induced apoptosis. Over-
expression of DN Ras, upstream of ERK1/2 activation,
blocks HGF inhibition of Ang II-induced apoptosis. These
ﬁndings further suggest that other growth factors that suf-
ﬁciently activate the MEK/ERK pathway will also inhibit
Ang II-induced translocation of nucleolin to the nucleus and
its disassociation from the Bcl-xL mRNA with subsequent
down-regulation of Bcl-xL protein and apoptosis.
Our data also indicate that HGF promotes the binding of
the protein nucleolin to the Bcl-xL mRNA to prevent Ang
II-induced reduction of this mRNA. The multifunctional
protein nucleolin binds to RNA and DNA and plays roles in
proliferation, apoptosis, and differentiation (Sengupta et al.,
2004). In the cytoplasm, nucleolin protects Bcl-2 and Bcl-xL
mRNAs from degradation by binding to AU-rich regions of
the 3-UTRs, thus contributing to cell survival by stabilizing
the levels of these anti-apoptotic members of the Bcl-2 family
(Sengupta et al., 2004; Otake et al., 2007). Previously, we
found that Ang II caused a decrease in Bcl-xL mRNA half-
life by reducing the nucleolin binding to the second AU-rich
region of the UTR of the mRNA (Lee et al., 2010). We
demonstrated that although nucleolin binds to both Bcl-xL
and Bcl-2 mRNA in EC, Ang II treatment speciﬁcally re-
duces nucleolin binding to Bcl-xL but not to Bcl-2 (Lee et al.,
2010). This was reﬂected in the reduction of Bcl-xL protein
but not of Bcl-2 protein, suggesting Bcl-2 protein does not
play a major role in Ang II-induced apoptosis.
Several studies have indicated that nucleolin protein
might play a pivotal role in the balance between cell survival
and apoptosis. Down-regulation of nucleolin, by small in-
terfering RNA or by agents that cause its degradation, is
sufﬁcient to induce growth arrest and apoptosis (Kito et al.,
2003; Ugrinova et al., 2007). Nucleolin can be regulated
through proteolysis, methylation, ADP-ribosylation, and
phosphorylation (Srivastava and Pollard, 1999). Speciﬁc
phosphorylations affect nucleolin’s stability and subcellular
localization (Schwab and Dreyer, 1997). In the cytoplasm,
nucleolin plays a role in cell survival but its translocation to
the nucleus is associated with proapoptotic events (Schwab
and Dreyer, 1997). In the cytoplasm, nucleolin can be phos-
phorylated by protein kinase C (PKC), cyclic AMP-depen-
dent protein kinase (PKA), and ectoprotein kinase (Srivas-
tava and Pollard, 1999). Nucleolin contains its own nuclear
translocation signal, but nuclear translocation of nucleolin
requires dephosphorylation (Schwab and Dreyer, 1997). In
the nucleus, nucleolin can be phosphorylated on serine res-
idues by the cell cycle-regulated kinases casein kinase II and
cell division cycle 2 protein, resulting in its localization back
to the cytoplasm (Peter et al., 1990; Bouche et al., 1994). We
recently determined that Ang II-induced nuclear transloca-
tion of nucleolin and its dissociation from Bcl-xL mRNA
Figure 8. HGF-activated ERK1/2 is necessary
to inhibit apoptosis in rat lung ex vivo explants.
(A) Ex vivo rat lung slices were treated with
Ang II (10 M)  U0126 (10 M) and/or HGF
(25 ng/ml) overnight. The tissue was homoge-
nized, and the protein lysates were used for
Western blots to determine the expression level
of cleaved caspase-3. ERK1/2 phosphorylation
by HGF was determined after 10 min of treat-
ment with HGF (25 ng/ml)  U0126 (10 M).
Equal amounts of protein lysates were immu-
noblotted for phospho-ERK1/2 (p-ERK1/2);
blots were stripped and blotted for total
ERK1/2 as a control. Panel to the right shows
densitometry of p-ERK1/2 normalized to total
ERK1/2. (B) Rat lung tissue slice cultures were
infected with adenovirus GFP or DN MEK for
48 h, followed by treatment overnight with
Ang II (10 M)  HGF (25 ng/ml). Tissues
were homogenized, and whole cell lysates
were used to run western blots for p-ERK1/2
and cleaved caspase-3; blots were stripped and
probed for total ERK1/2 and -actin, respec-
tively, for protein loading controls. For all bar
graphs, data show means  SD. Asterisk (*)
indicates statistical signiﬁcance from control,
p  0.05, n  3. Experiments were repeated at
least three times.
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(Lee et al., 2010). We also determined that neither PKC nor
PKA affected apoptosis by Ang II (Lee et al., 2010), suggest-
ing that these two kinases are not involved in this pathway.
The exact mechanism of the effect of ERK activation on
nucleolin is not known. This issue is currently under inves-
tigation in our laboratory.
Our work also demonstrates that HGF inhibits Ang II-
induced apoptosis in lung tissue ex vivo. Studies using the
ex vivo method have indicated that alveolar cells divide and
correctly differentiate in ex vivo lung slice cultures (Kinnard
et al., 1994), and this technique has been used for apoptosis
and cell survival studies (Li et al., 2003; Lang et al., 2007;
Hackett et al., 2008). The in vivo mechanism(s) of HGF-
induced cell survival is currently being investigated in our
laboratory. The identiﬁcation of key downstream signaling
for the inhibition of cellular apoptosis during the progres-
sion of ﬁbrosis may lead to the development of novel drug
targets for this disease.
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